$NKTR (Nektar Therapeutics)

$NKTR {{ '2015-12-08T15:08:32+0000' | timeago}} • Announcement

Biopharmaceutical company $NKTR said it has commenced dosing in the Phase 1/2 clinical study of the usage of NKTR-214 in the treatment of solid tumors. NKTR-214 is an immuno-oncology candidate that is designed to activate and multiply the patient's own tumor-killing T cells in order to fight cancer more effectively.

$ABMD {{ '2017-09-20T21:54:10+0000' | timeago}} • Announcement

$ABMD received US FDA pre-market approval for the Impella RP heart pump. The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients who develop acute right heart failure or decompensation following left ventricular assist device implantation, heart transplant, or open-heart surgery.

$PFE {{ '2017-09-20T18:14:48+0000' | timeago}} • Announcement

$PFE filed a lawsuit against $JNJ over anticompetitive practices. The lawsuit alleges J&J violated federal antitrust laws by signing exclusionary contracts with health insurers, hospitals and doctor groups to ensure its medicine Remicade was given preferential treatment over Pfizer's new biosimilar Inflectra.

$CELG {{ '2017-09-19T18:41:27+0000' | timeago}} • Announcement

After collaborating with $CELG for almost a decade, $XLRN amended its development and commercial agreement with Celgene for the investigational drug Sotatercept. Acceleron will develop and market Sotatercept in the pulmonary hypertension field. Celgene will be eligible to receive royalties on global net sales in that field.

$MDT {{ '2017-09-18T13:29:52+0000' | timeago}} • Announcement

$MDT announced FDA approval and U.S. launch of the Intellis platform for the management of certain types of chronic intractable pain. The Intellis platform was designed to overcome limitations with current spinal cord stimulation (SCS) systems, such as battery performance, and can power the Evolve workflow.

$ABT {{ '2017-09-18T12:47:46+0000' | timeago}} • Announcement

$ABT is extending its previously announced tender offer to purchase all outstanding shares of Series B Convertible Perpetual Preferred Stock of Alere Inc. for $402 per share of Preferred Stock. The offer is being extended to allow additional time for the consummation of the merger, which is a condition to the completion of the offer.

$AMGN {{ '2017-09-14T19:26:48+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi for the treatment of five types of cancer. Amgen and Allergan's bevacizumab biosimilar is also undergoing review by the European Medicines Agency, following a Marketing Authorization Application submitted in December 2016.

$AMGN {{ '2017-09-14T19:26:21+0000' | timeago}} • Announcement

$AMGN and $AGN said the FDA has approved their Mvasi (bevacizumab-awwb) for the treatment of five types of cancer. The approval was based on totality of evidence from global development program showing Mvasi is highly similar to Avastin. Mvasi is the first anti-cancer biosimilar, as well as first bevacizumab biosimilar, approved by the FDA.

$ABT {{ '2017-09-14T16:50:10+0000' | timeago}} • Announcement

$ABT BoD declared a quarterly common dividend of $0.265 per share. The dividend is payable Nov. 15, 2017, to shareholders of record at the close of business on Oct. 13, 2017.

$LLY {{ '2017-09-14T15:00:58+0000' | timeago}} • Announcement

$LLY and $INCY announced that new data from Phase 2 study of atopic dermatitis drug Baricitinib showed better outcomes. Atopic dermatitis is a type of inflammation of the skin, which results in itchy and red skin. Lilly and Incyte plans to start Phase 3 clinical program for atopic dermatitis later this year.

$BMY {{ '2017-09-13T20:46:25+0000' | timeago}} • Announcement

$BMY declared a quarterly dividend of $0.39 per share on the $.10 par value common stock of the corporation. The next quarterly dividend will be payable on November 1, 2017, to stockholders of record at the close of business on October 6, 2017.

$BMY {{ '2017-09-13T20:29:36+0000' | timeago}} • Announcement

$BMY elected Karen Vousden, effective Jan 1, 2018. to serve as a member of the Science and Technology Committee of the Board of Directors. Dr. Vousden is currently group leader at the Francis Crick Institute in London and the Chief Scientist at Cancer Research UK.

$NKTR {{ '2017-09-12T13:42:15+0000' | timeago}} • Announcement

$NKTR began dosing in Propel study to gauge the efficacy of NKTR-214, its immuno-oncology therapy in tandem with approved checkpoint inhibitors, TECENTRIQ (atezolizumab) and KEYTRUDA (pembrolizumab). NKTR-214 can expand specific cancer-fighting T cells and natural killer cells in the tumor microenvironment and up expression of PD-1 on these cells.

$COO {{ '2017-09-11T20:51:49+0000' | timeago}} • Announcement

Medical devices company $COO has signed an agreement with pharma firm $TEVA to acquire the global rights and business of Teva’s Paragard Intrauterine Device for $1.1Bil in cash. The transaction, which is likely to close prior to the end of the calendar year, is expected to be accretive to Cooper's earnings by $0.7-0.75 per share in the first year.

$TEVA {{ '2017-09-11T20:47:29+0000' | timeago}} • Announcement

Israeli drugmaker $TEVA appointed Kare Schultz as its CEO replacing the current acting CEO Yitzhak Peterburg, who will continue as acting CEO until Schultz joins. Schultz, who will move to Israel and be based at Teva's headquarters, recently served as CEO of Denmark-based H. Lundbeck A/S. Prior to this job, he held the post of COO in Novo Nordisk.

$MRK {{ '2017-09-11T17:08:33+0000' | timeago}} • Announcement

$MRK announced that Keytruda is the only programmed death (PD-1) drug with data to show it can improve overall survival rate in the second-line bladder cancer. Phase 3 results show that patients whose disease had progressed following platinum chemo treatment, Keytruda demonstrated an OS advantage vs. chemo with median follow-up of 22.5 months.

$MDT {{ '2017-09-11T12:01:51+0000' | timeago}} • Announcement

$MDT voluntarily recalls specific lots of infusion sets used with all models of Medtronic insulin pumps due to a certain discontinued component. The recall comes after reports from patients that a component, the vent membrane, may be susceptible to being blocked by fluid during priming and fill-tubing, which can lead to over-delivery of insulin.

$BMY {{ '2017-09-11T10:59:32+0000' | timeago}} • Announcement

$BMY said Opdivo plus Yervoy combination demonstrated superior overall survival and showed durable responses in patients with previously untreated advanced or metastatic renal cell carcinoma in phase 3 CheckMate -214 trial. The combination lowered the risk of death by 37% and improved overall survival in all randomized patients.

$AGN {{ '2017-09-08T19:54:30+0000' | timeago}} • Announcement

$AGN transferred all patents for its dry eye treatment drug Restasis to the St. Regis Mohawk tribe to protect the drug patents. The tribe has granted Allergan back an exclusive license for the drug. As per the agreement, the tribe will get $13.75MM as one-time payment, and potentially $15MM annually in royalties.

$ABBV {{ '2017-09-08T16:14:15+0000' | timeago}} • Announcement

$ABBV's BoD declared a quarterly cash dividend of $0.64 per share. The dividend is payable on Nov. 15, 2017 to stockholders of record on Oct. 13, 2017. Since the company's inception in 2013, $ABBV has increased its dividend by 60%.

$CELG {{ '2017-09-08T15:34:27+0000' | timeago}} • Announcement

$CELG to present data from multiple studies about the use of Abraxane to treat non-small lung cancer and pancreatic cancer. The data will be presented at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting between Sept 8-12 in Madrid, Spain.

Recent Transcripts

MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
NKTR (Nektar Therapeutics)
Tuesday, August 8 2017 - 9:00pm
DRRX (DURECT Corporation)
Tuesday, August 8 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
INSM (Insmed Incorporated)
Thursday, August 3 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, August 3 2017 - 12:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, August 3 2017 - 11:30am
BMRN (BioMarin Pharmaceutical Inc.)
Wednesday, August 2 2017 - 8:30pm
INCY (Incyte Corporation)
Tuesday, August 1 2017 - 2:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
ABMD (ABIOMED, Inc.)
Thursday, July 27 2017 - 12:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
TEVA (Teva Pharmaceutical Industries Limited)
Thursday, May 11 2017 - 12:00pm

AlphaGraphics you may like